GLP-1 & compounded medication availability in Idaho (2026)
Idaho runs one of the leanest pharmacy codes in the country. The state spent the last decade stripping its rules back to licensure and practice standards rather than medication-by-medication carve-outs, and its virtual-care law is unusually explicit that telehealth is a valid way to start care. Here is what actually ships to Idaho addresses across all ten product lines we track, and what the state’s pharmacy regulators expect of out-of-state pharmacies like our partners.
What ships to Idaho: all ten lines
| Product line | Available in Idaho? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Ships to Idaho addresses from licensed partner pharmacies. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | Same flat national price at every dose level. |
| NAD+ | Yes | 8–10 business days | Longevity line; identical ordering flow. |
| Sermorelin | Yes | 8–10 business days | Ships from licensed partner pharmacies. |
| Glutathione | No | N/A | Not in the OrderlyMeds formulary today. |
| BPC-157 | Yes | 8–10 business days | Compounded injectable. Its federal record is stated below. |
| TB-500 | Yes | 8–10 business days | Compounded injectable; see its own section below. |
| KPV | No | N/A | Not carried, since we compound these lines as injectables only. |
| Epitalon | Yes | 8–10 business days | Compounded injectable; federal picture below. |
| MOTS-c | Yes | 8–10 business days | Compounded injectable; its federal record is its own, below. |
A “No” is a fact, not a gap in the page, and we would rather show it than hide the row. Idaho facts on this page were last reviewed on November 16, 2026.
Research peptides in Idaho: BPC-157, TB-500, KPV, Epitalon & MOTS-c
OrderlyMeds carries four of these five lines for Idaho addresses: BPC-157, TB-500, Epitalon and MOTS-c, each compounded as an injectable and dispensed on a patient-specific prescription. KPV is the exception: our peptide lines are injectables, and KPV is not one of them. Below, each line’s federal record is stated on its own terms, whether or not it ships to you. The five are often lumped together, and their records are not interchangeable.
BPC-157 in Idaho
In the formulary for Idaho as a compounded injectable, dispensed on a patient-specific prescription. The two federal facts below apply in full.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in Idaho
Ships to Idaho addresses as a compounded injectable under a patient-specific prescription. Its federal record is below.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in Idaho
Not shipped to Idaho, or anywhere. Our peptide lines are injectables, and KPV is not among them.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in Idaho
Available to Idaho patients as a compounded injectable on a patient-specific prescription. The federal facts below are unchanged by that.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in Idaho
Carried for Idaho as a compounded injectable, patient-specific prescription required. Its federal record is its own, so read it as written.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What Idaho’s pharmacy regulators say about compounded medications
Idaho’s approach is licensure-first and deliberately lean: the state rewrote its pharmacy rules over the past decade to regulate who may practice and to what standard, rather than keeping per-category medication rules. For an Idaho patient ordering through telehealth, what matters is that the prescriber can practice into Idaho, the pharmacy is registered for Idaho, and the prescription is written for you specifically.
Idaho’s Pharmacy Act addresses compounding directly — Idaho Code §§ 54-1765 through 54-1767 cover compounding, sterile compounding, and hazardous-drug handling — and no GLP-1-specific or peptide-specific prohibition appears in the board’s published act. Source: Idaho Legislature — Pharmacy Act (Title 54, ch. 17).
Out-of-state pharmacies shipping prescription drugs to Idaho patients must register with the state as nonresident drug outlets under the Pharmacy Act’s registration provisions. Source: Idaho Legislature — Pharmacy Act (Title 54, ch. 17).
Idaho’s Virtual Care Access Act permits a provider-patient relationship to be established through virtual care and permits prescriptions to be issued on the basis of such an encounter (Idaho Code §§ 54-5705, 54-5707). Source: Idaho Legislature — Virtual Care Access Act (Title 54, ch. 57).
An Idaho order runs the standard OrderlyMeds path end to end: online eligibility check, telehealth evaluation with a provider licensed for Idaho, fulfillment by a licensed partner pharmacy registered for the state, mail delivery. Pricing is national. The price on our pricing page is the Idaho price at every dose.
Idaho availability FAQs
Is compounded semaglutide available in Idaho?
Yes. OrderlyMeds ships compounded semaglutide to Idaho addresses from licensed partner pharmacies, starting at $74/month for the first two months for new customers.
Can I start in Idaho without an office visit?
Yes. Idaho's virtual-care framework is explicit on this point, and the cited detail is in the regulator section above. Your evaluation happens online with a provider licensed for Idaho.
Do BPC-157 or the other research peptides ship to Idaho?
BPC-157, TB-500, Epitalon and MOTS-c do, as compounded injectables under patient-specific prescriptions. KPV does not, because we compound these lines as injectables only. Each one's federal record is stated in its own section above.
How long does delivery to Idaho take?
Our published window is 8–10 business days from signup, the same nationwide.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
